Anzeige
Mehr »
Montag, 15.09.2025 - Börsentäglich über 12.000 News
Jetzt investieren - "Neubewertung Extrem" durch Übernahme?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von PMLiVE

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
04.08.The power of representation, innovation and trust in rare disease clinical trials
01.08.Sanofi's Sarclisa approved by EC to treat newly diagnosed multiple myeloma
01.08.Eli Lilly's Alzheimer's disease drug donanemab recommended by CHMP
01.08.Patient engagement - a journey of health activation
31.07.Merck unveils $3bn cost-cutting plan to support pipeline and new product launches
31.07.Havas Lynx appoints Talin Apkarian as Havas Lynx Hudson managing director
30.07.Moderna's LP.8.1-adapted COVID-19 vaccine recommended by CHMP
30.07.Havas Lynx appoints Ayesha Walawalkar as chief strategy officer
29.07.AstraZeneca's Imfinzi granted FDA priority review to treat early-stage gastric cancer
29.07.Roche shares promising data from Alzheimer's disease development portfolio
28.07.AbbVie's Elahere granted MHRA approval to treat platinum-resistant ovarian cancer
28.07.J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma
25.07.Novartis and Matchpoint enter inflammatory disease partnership worth $1bn
25.07.GSK's Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma
25.07.Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies
24.07.Johnson & Johnson's Darzalex approved by EC as first treatment for high-risk SMM
24.07.LEO's Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema
24.07.Abivax shares positive late-stage results for obefazimod in ulcerative colitis
23.07.AstraZeneca unveils plans to boost US footprint with $50bn investment
23.07.Roche's Itovebi granted EC approval to treat advanced breast cancer patients
23.07.NICE recommends ALK's immunotherapy to target underlying cause of hay fever
23.07.FDA appoints George Tidmarsh as director of CDER
22.07.Biogen to boost US manufacturing footprint with $2bn North Carolina investment
22.07.Eli Lilly/Almirall's Ebglyss shows promise in atopic dermatitis patients with darker skin tones
22.07.Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition